LeMaitre Vascular (NASDAQ:LMAT) had its price objective cut by Canaccord Genuity from $40.00 to $32.00 in a report issued on Monday morning, The Fly reports. They currently have a hold rating on the medical instruments supplier’s stock.

Other equities analysts also recently issued research reports about the stock. ValuEngine upgraded shares of LeMaitre Vascular from a hold rating to a buy rating in a research note on Friday, June 15th. BidaskClub raised shares of LeMaitre Vascular from a hold rating to a buy rating in a research report on Thursday, June 28th. Lake Street Capital assumed coverage on shares of LeMaitre Vascular in a research report on Monday, June 25th. They set a buy rating and a $45.00 price objective for the company. Roth Capital cut shares of LeMaitre Vascular from a buy rating to a neutral rating and lifted their price objective for the stock from $38.00 to $39.00 in a research report on Tuesday, October 2nd. Finally, Zacks Investment Research cut shares of LeMaitre Vascular from a hold rating to a sell rating in a research report on Wednesday, September 26th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company’s stock. LeMaitre Vascular presently has an average rating of Hold and an average target price of $35.63.

NASDAQ:LMAT opened at $27.31 on Monday. The firm has a market capitalization of $748.16 million, a price-to-earnings ratio of 31.70, a price-to-earnings-growth ratio of 2.42 and a beta of 0.63. LeMaitre Vascular has a 52 week low of $26.45 and a 52 week high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.21. The business had revenue of $24.17 million during the quarter, compared to the consensus estimate of $26.06 million. LeMaitre Vascular had a net margin of 21.09% and a return on equity of 19.49%. Sell-side analysts forecast that LeMaitre Vascular will post 1.07 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 6th. Stockholders of record on Tuesday, November 20th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Monday, November 19th. This represents a $0.28 annualized dividend and a dividend yield of 1.03%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 32.56%.

In other news, Director David B. Roberts sold 21,005 shares of LeMaitre Vascular stock in a transaction on Thursday, August 2nd. The shares were sold at an average price of $35.72, for a total transaction of $750,298.60. Following the completion of the sale, the director now directly owns 5,373 shares of the company’s stock, valued at approximately $191,923.56. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Chairman George W. Lemaitre sold 39,820 shares of LeMaitre Vascular stock in a transaction on Friday, July 27th. The stock was sold at an average price of $37.34, for a total transaction of $1,486,878.80. Following the sale, the chairman now directly owns 3,085,291 shares of the company’s stock, valued at $115,204,765.94. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 97,506 shares of company stock valued at $3,608,759. Corporate insiders own 20.30% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its position in LeMaitre Vascular by 4.0% in the second quarter. BlackRock Inc. now owns 2,425,454 shares of the medical instruments supplier’s stock valued at $81,202,000 after acquiring an additional 93,615 shares during the last quarter. Conestoga Capital Advisors LLC lifted its position in LeMaitre Vascular by 8.9% in the second quarter. Conestoga Capital Advisors LLC now owns 1,392,591 shares of the medical instruments supplier’s stock valued at $46,624,000 after acquiring an additional 113,705 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in LeMaitre Vascular by 0.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,006,078 shares of the medical instruments supplier’s stock valued at $33,684,000 after acquiring an additional 2,824 shares during the last quarter. Epoch Investment Partners Inc. lifted its position in LeMaitre Vascular by 20.8% in the second quarter. Epoch Investment Partners Inc. now owns 932,093 shares of the medical instruments supplier’s stock valued at $31,207,000 after acquiring an additional 160,754 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in LeMaitre Vascular by 14.4% in the second quarter. Janus Henderson Group PLC now owns 691,670 shares of the medical instruments supplier’s stock valued at $23,157,000 after acquiring an additional 87,197 shares during the last quarter. 79.75% of the stock is owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Recommended Story: How Do You Calculate Return on Equity (ROE)?

The Fly

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.